Shield Therapeutics has announced its 1Q26 trading update, demonstrating strong progress both on a commercial basis and in terms of the continuing regulatory and pipeline development of ACCRUFeR®. Group net revenues were $18m, with ACCRUFeR net revenues up 54% YOY to $9.9m. The combination of strong US ACCRUFeR sales and the $7.9m development milestone payment by ASK in China delivered positive EBIT of $2.5m (1Q25: $4.4m loss). Shield’s CFO, Santosh Shanbhag, will step down from his role effecti ....
